"Those with the highest burden of comorbidity had over a 30% increased risk of having disability worsening," Salter said. "In ...

A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...

Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...

Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous ...

A study has uncovered novel ancestry-specific genetic variants linked to multiple sclerosis (MS), offering new insights that ...

Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the ...

Available disease-modifying therapies can prevent relapses and relapse-associated worsening in people with multiple sclerosis by targeting autoimmunity through various mechanisms. However, these ...

Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...

High dietary salt intake may activate a novel molecular pathway that could trigger autoimmune diseases such as multiple ...

Patients with MS showed half the rate of amyloid pathology compared with people without MS, suggesting a possible protective ...

The U.S. Food and Drug Administration on Thursday approved Roche's under-the-skin injection to treat patients with multiple ...

Tolebrutinib delayed the onset of disability progression by 31% for patients with a type of the disease called non-relapsing ...